Efgartigimod PH20 SC for adults with primary immune thrombocytopenia

Efgartigmod PH20 SC is currently in phase 3 development for the treatment of adults with primary immune thrombocytopenia (ITP). ITP is a rare disorder that makes the blood clot poorly due to low levels of platelets, the cells that plug wounds. ITP can cause bleeding under the skin, in the mouth, nose or other organs. It is caused through a malfunction in the immune system that attacks and destroys platelets. The exact trigger is unknown but some cases are linked to infections, drugs or other diseases. ITP is currently treated with drugs that suppress the immune system, boost platelet production, or prevent bleeding.